71186-53-3

中文名稱 5-羥基癸酸鈉

英文名稱 5-HYDROXYDECANOIC ACID SODIUM SALT

CAS 71186-53-3

分子式 C10H19NaO3

分子量 210.25

MOL 文件 71186-53-3.mol

71186-53-3 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 5-羥基癸酸鈉價格(試劑級) 常見問題列表

基本信息

中文別名

化合物5-HYDROXYDECANOATE SODIUM

英文別名

5-HYDROXYDECANOATE NA
5-Hydroxydecanoate sodium
Sodium 5-hydroxydecanoate
5-HYDROXYDECANOIC ACID SODIUM
5-HYDROXYDECANOIC ACID SODIUM SALT
5-Hydroxydecanoic acid sodium salt,5-hydroxydecanoate sodium salt

物理化學(xué)性質(zhì)

儲存條件desiccated

溶解度H₂O: soluble

形態(tài)solid

顏色white

水溶解性H2O: 10mg/mL, clear

InChI1S/C10H20O3.Na/c1-2-3-4-6-9(11)7-5-8-10(12)13;/h9,11H,2-8H2,1H3,(H,12,13);/q;+1/p-1

InChIKeyYNAGNECWEKMWRM-UHFFFAOYSA-M

SMILES[Na+].CCCCCC(O)CCCC([O-])=O

安全數(shù)據(jù)

WGK Germany3

存儲類別11 - Combustible Solids

圖譜信息

5-羥基癸酸鈉(71186-53-3)核磁圖(¹HNMR)

5-羥基癸酸鈉價格(試劑級)

報價日期	產(chǎn)品編號	產(chǎn)品名稱	CAS號	包裝	價格
2026/06/05	HY-136615	5-羥基癸酸鈉 5-Hydroxydecanoate sodium	71186-53-3	5 mg	230元
2026/06/05	HY-136615	5-羥基癸酸鈉 5-Hydroxydecanoate sodium	71186-53-3	10mM * 1mLin DMSO	253元
2026/06/05	HY-136615	5-羥基癸酸鈉 5-Hydroxydecanoate sodium	71186-53-3	10 mg	346元

常見問題列表

生物活性

5-Hydroxydecanoate sodium 是一種選擇性 ATP 敏感的 K+ (KATP) 通道阻滯劑 (IC50 約為 30 μM)。5-Hydroxydecanoate sodium 是線粒體外膜酰基輔酶 A 合成酶的底物，并具有抗氧化活性。

靶點

IC50: ~30 μM (K _ATP )

體外研究

5-Hydroxydecanoate (5-HD) treatment abolishs the beneficial effects of penehyclidine hydrochloride (PHC) preconditioning in anoxia/reoxygenation (A/R)‐induced injury in H9c2 cells. 5-Hydroxydecanoate blocks the inhibitory effect of PHC on Ca ²⁺ overload and ROS production. 5-Hydroxydecanoate promotes the release of Cyt-C from mitochondria into cytoplasm. 5-Hydroxydecanoate attenuats the anti-apoptotic effect of PHC. PHC treatment shows remarkably decreases levels of Bax and cleaved caspase-3, and increases levels of Bcl-2. 5-Hydroxydecanoate pretreatment reverses the effects of PHC on their expression levels. 5-Hydroxydecanoate blocks the effects of PHC on K _ATP channels.

體內(nèi)研究

5-Hydroxydecanoate (100 μM) treatment abolishes the effects of ischemic preconditioning (IPC) on the contractile recovery and does not affect its effect on the contracture, lactate production, glycogenolysis and viable tissue in rats.